Ulna fracture

Summary

Ulna fracture (MONDO:0005322) is a disease and 5 clinical trials. Top therapeutic interventions include ropivacaine. A subtype of bone fracture — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ulna fracture
Mondo ID	MONDO:0005322
EFO	EFO:0003950
MeSH	D014458
SNOMED CT	54556006
Anatomy (UBERON)	UBERON:0001424
Is cancer (heuristic)	no

Also known as: bone fracture of ulna · ulna bone fracture

Disease family

This is a subtype of bone fracture. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: injury › bone fracture › ulna fracture

Related subtypes (6): spinal fracture, humerus fracture, tibia fracture, radius fracture, hip fracture, jaw fracture

Subtypes (1): Monteggia’s fracture

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02630290	PHASE4	COMPLETED	Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)
NCT07536581	Not specified	NOT_YET_RECRUITING	Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails
NCT01123447	Not specified	UNKNOWN	Surgical Treatment Versus Non-surgical Treatment of Ulnar Fractures
NCT05329012	Not specified	COMPLETED	Prospective Case Series to Assess Complications of Using Distal Ulna Locking Plate of I.T.S.
NCT06304649	Not specified	UNKNOWN	Clinical Evaluation of Cast21 Short Arm Product During Treatment of Distal Radial or Distal Ulnar Fractures

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROPIVACAINE	4	1